147 related articles for article (PubMed ID: 36805873)
21. Delivering co-stimulatory tumor necrosis factor receptor agonism for cancer immunotherapy: past, current and future perspectives.
Dadas O; Ertay A; Cragg MS
Front Immunol; 2023; 14():1147467. PubMed ID: 37180119
[TBL] [Abstract][Full Text] [Related]
22. Engineering bacteria for cancer immunotherapy.
Zalatan JG; Petrini L; Geiger R
Curr Opin Biotechnol; 2024 Feb; 85():103061. PubMed ID: 38219524
[TBL] [Abstract][Full Text] [Related]
23. Harnessing Antitumor Immunity in Ovarian Cancer.
Kurnit KC; Odunsi K
Cold Spring Harb Perspect Med; 2024 Apr; ():. PubMed ID: 38621830
[TBL] [Abstract][Full Text] [Related]
24. Beyond the danger signal: RNA aggregates orchestrate immunotherapy.
Shubhra QTH; Feczkó T; Cai Q
Trends Mol Med; 2024 Jun; ():. PubMed ID: 38866645
[TBL] [Abstract][Full Text] [Related]
25. Correction: Microenvironment of pancreatic inflammation: calling for nanotechnology for diagnosis and treatment.
Liu L; Zhang Y; Li X; Deng J
J Nanobiotechnology; 2024 Jan; 22(1):38. PubMed ID: 38263033
[No Abstract] [Full Text] [Related]
26. Ultrasound in Cancer Treatment through Nanotechnology.
Beik J; Mehdizadeh AR; Shakeri-Zadeh A
J Biomed Phys Eng; 2016 Sep; 6(3):123-126. PubMed ID: 27853719
[No Abstract] [Full Text] [Related]
27. d-lactate modulates M2 tumor-associated macrophages and remodels immunosuppressive tumor microenvironment for hepatocellular carcinoma.
Han S; Bao X; Zou Y; Wang L; Li Y; Yang L; Liao A; Zhang X; Jiang X; Liang D; Dai Y; Zheng QC; Yu Z; Guo J
Sci Adv; 2023 Jul; 9(29):eadg2697. PubMed ID: 37467325
[TBL] [Abstract][Full Text] [Related]
28. Macrophages at the interface of the co-evolving cancer ecosystem.
Kloosterman DJ; Akkari L
Cell; 2023 Apr; 186(8):1627-1651. PubMed ID: 36924769
[TBL] [Abstract][Full Text] [Related]
29. Nanoparticle pre-treatment for enhancing the survival and activation of pulmonary macrophage transplant.
Jarai BM; Bomb K; Fromen CA
Drug Deliv Transl Res; 2023 Jul; 13(7):1955-1966. PubMed ID: 36917409
[TBL] [Abstract][Full Text] [Related]
30. Spatial-Drug-Laden Protease-Activatable M1 Macrophage System Targets Lung Metastasis and Potentiates Antitumor Immunity.
Xu X; Wang Q; Qian X; Wu Y; Wang J; Li J; Li Y; Zhang Z
ACS Nano; 2023 Mar; 17(6):5354-5372. PubMed ID: 36877635
[TBL] [Abstract][Full Text] [Related]
31. Engineering customized nanovaccines for enhanced cancer immunotherapy.
Guo J; Liu C; Qi Z; Qiu T; Zhang J; Yang H
Bioact Mater; 2024 Jun; 36():330-357. PubMed ID: 38496036
[TBL] [Abstract][Full Text] [Related]
32. Nanoparticle-Based Immunotherapy for Reversing T-Cell Exhaustion.
Li F; Wang Y; Chen D; Du Y
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338674
[TBL] [Abstract][Full Text] [Related]
33. A new approach to overcoming resistance to immunotherapy: nanotechnology.
Shao J; Jin Y; Jin C
Front Oncol; 2023; 13():1210245. PubMed ID: 37637050
[TBL] [Abstract][Full Text] [Related]
34. Advances in Cancer Nanovaccines: Harnessing Nanotechnology for Broadening Cancer Immune Response.
Wang QT; Liu YX; Wang J; Wang H
ChemMedChem; 2023 Jul; 18(13):e202200673. PubMed ID: 37088719
[TBL] [Abstract][Full Text] [Related]
35. Nanoscale Metal-Organic Frameworks for Cancer Immunotherapy.
Ni K; Luo T; Nash GT; Lin W
Acc Chem Res; 2020 Sep; 53(9):1739-1748. PubMed ID: 32808760
[TBL] [Abstract][Full Text] [Related]
36. Modulating barriers of tumor microenvironment through nanocarrier systems for improved cancer immunotherapy: a review of current status and future perspective.
Lan H; Zhang W; Jin K; Liu Y; Wang Z
Drug Deliv; 2020 Dec; 27(1):1248-1262. PubMed ID: 32865029
[TBL] [Abstract][Full Text] [Related]
37. Regulation of cancer-immunity cycle and tumor microenvironment by nanobiomaterials to enhance tumor immunotherapy.
Yang J; Zhang C
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Jul; 12(4):e1612. PubMed ID: 32114718
[TBL] [Abstract][Full Text] [Related]
38. Tumor-Targeted Nanomedicine for Immunotherapy.
Cabral H; Kinoh H; Kataoka K
Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
[TBL] [Abstract][Full Text] [Related]
39. Nanotechnology for next-generation cancer immunotherapy: State of the art and future perspectives.
Chen Y
J Control Release; 2023 Apr; 356():14-25. PubMed ID: 36805873
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
